The incidence of type 1 diabetes continues to increase, most notably in American Hispanic (HIS) youth. Type 1 diabetes autoimmunity has not been fully characterized in HIS youth. Determining the prevalence of islet autoantibody positivity in HIS youth may improve understanding of T1D immunopathogenesis and potentially impact treatment. We determined the prevalence of islet autoantibodies directed against glutamic acid decarboxylase 65 (GADA) , insulinoma antigen-2 (IA-2A) , insulin (IAA) and zinc transporter 8 (ZnT8A) using fluid-phase radiobinding assays from stored sera in HIS youth (n=378) and in age/sex matched (9.4±4.0y, 48% male) non-Hispanic white (NHW) youth (n=378) with recent onset diabetes from our large diabetes center in Colorado. Of note, BMI was significantly lower in HIS youth (17±3.6 kg/m2) compared to NHW youth (20.0±7.1) (p=0.01) . HIS youth with type 1 diabetes had a higher rate of positivity for GADA and IA-2A when compared to NHW youth with type 1 diabetes (p<0.01, Figure) . HIS youth were also more likely to have 3 or more islet autoantibodies present at diagnosis compared to NHW youth (p=0.01) . Investigating the phenotype of diabetes in diverse racial and ethnic groups with type 1 diabetes provides an opportunity to further dissect the heterogeneity that exists within diabetes in youth.
K.M.Simmons: Advisory Panel; Provention Bio, Inc., Consultant; Dexcom, Inc. T.B.Vigers: None. L.Pyle: None. E.M.Youngkin: None. E.E.Baschal: None. K.Mcdaniel: None. L.Yu: None. A.W.Michels: Employee; ImmunoMolecular Therapeutics, Stock/Shareholder; ImmunoMolecular Therapeutics.
National Institutes of Health (K12DK094712)